Phase 2 data suggests retatrutide may produce greater weight reduction than currently approved agents, but its long-term safety profile has not been fully established, and no head-to-head regulatory-grade trials have been completed
Providing care beyond body size Patients on GLP-1s may have different vulnerabilities, and clinicians have different philosophies about how safe the drugs areand who should receive them
24/7 Customer Support Friendly support available anytime you need assistance
If you feel any lumps, hard spots, or persistent tenderness, avoid that zone for a while and let it recover
Find a primary care provider here.
Michaowska, J., Miller-Kasprzak, E., & Bogdaski, P